RESUMO
La diabetes mellitus tipo 1 (DM1), es una enfermedad crónica caracterizada por la deficiencia de insulina debido a la pérdida de células ß pancreáticas, las alteraciones hormonales en la DM 1 no se limitan a la deficiencia de insulina; existiendo también secreción inadecuadada de glucagón en el período postprandial. Aunque el control glucémico con terapias intensivas con insulina ha reducido la incidencia de complicaciones microvascular y macrovasculares. La mayoría de las personas con DM1 tienen un control glucémico subóptimo; Por lo tanto, el uso de farmacoterapia adyuvante para mejorar el control ha sido de interés clínico. El uso de estos nuevos medicamentos brindaría la oportunidad de imitar más de cerca la fisiología pancreática normal, y contrarrestar otros mecanismos fisiopatológicos diferentes a Insulinopenia; contribuyendo a lograr un mejor control metabólico y expectativa de vida.
Type 1 diabetes mellitus (T1DM), is a chronic disease characterized by insulin deficiency due to the loss of pancreatic ß cells, the hormonal alterations in T1DM are not limited to insulin deficiency; there is also a deregulated glucagon secretion in the postprandial period. Although glycemic control with intensive therapies with insulin has reduced the incidence of microvascular and macrovascular complications, most people with T1DM1 glycemic control; therefore, the use of adjuvant pharmacotherapy to improve control has been of clinical interest. The use of these new drugs would offer the opportunity to imitate more closely the normal pancreatic physiology, and to counteract other physiopathological mechanisms different from insulinopenia; contributing to achieve better metabolic control and life expectancy.
Assuntos
Humanos , Diabetes Mellitus Tipo 1/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Quimioterapia Adjuvante , Peptídeo 1 Semelhante ao Glucagon/uso terapêutico , Transportador 2 de Glucose-Sódio/antagonistas & inibidores , Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Metformina/uso terapêuticoRESUMO
Current therapies of diabetes proven to lowering glucose include metformin,TZDs,sulphanylureas,nateglinide,Repaglinide,acarbose and insulin analogues.Given our better understanding of the beta cell function are slowly emerging.Recently,the gastrointestinal peptide hormones glucagon-like peptide 1 analogues and inhibitors of dipeptidyl peptidase-4(DPP-4) have been shown to significantly contribute to glucose homeostasis.Meanwhile,other novel prospect for diabetes such as selective peroxisome proliferator-activated receptor(PPAR) gamma modulators,inhibitors of sodium glucose co-transporters 2 have been proven to be attractive drug candidates.The therapeutic potential of these molecules are discussed in this review.